Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, has received approval for its innovative GLP-1R/GCGR dual target drug, P052 injection, for the treatment of type 2 diabetes and obesity. This approval highlights Huisheng Biopharmaceutical’s strong R&D capabilities and positions the company to capture significant market potential in the expanding diabetes treatment sector in China, where diabetes and obesity rates are rising. The P052 injection is expected to compete with existing treatments like Semaglutide, offering improved weight loss effects and enhancing the company’s competitiveness and market value in the diabetes industry.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Huisheng Biopharmaceutical, a subsidiary of Sihuan Pharmaceutical Holdings Group, is a biopharmaceutical company focusing on diabetes and related complications. It has developed a comprehensive product line covering diabetes drugs and integrated the entire industrial chain of R&D, production, and sales. The company is recognized for its world-class R&D team and innovative diabetes treatment solutions.
Average Trading Volume: 112,799,752
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.39B
For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.